Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $222.7 million.

  • Ultragenyx Pharmaceutical's Short-term Investments fell 5270.84% to $222.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $222.7 million, marking a year-over-year decrease of 5270.84%. This contributed to the annual value of $436.3 million for FY2024, which is 1998.51% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Short-term Investments is $222.7 million, which was down 5270.84% from $311.3 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Short-term Investments high stood at $614.8 million for Q4 2022, and its period low was $222.7 million during Q3 2025.
  • For the 5-year period, Ultragenyx Pharmaceutical's Short-term Investments averaged around $429.8 million, with its median value being $436.3 million (2024).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Short-term Investments surged by 5930.79% in 2021 and then tumbled by 5270.84% in 2025.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Short-term Investments stood at $432.6 million in 2021, then soared by 42.12% to $614.8 million in 2022, then crashed by 40.86% to $363.6 million in 2023, then grew by 19.99% to $436.3 million in 2024, then plummeted by 48.95% to $222.7 million in 2025.
  • Its last three reported values are $222.7 million in Q3 2025, $311.3 million for Q2 2025, and $367.4 million during Q1 2025.